Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

NCT05544968 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT05544968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05544968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Recruiting
Start date
March 4, 2026
Completion date
July 31, 2029
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd30+ anaplastic large cell lymphoma, cd30+ immunoblastic large t-cell cutaneous lymphoma, cd30+ pleomorphic large t-cell cutaneous lymphoma, cd30-positive diffuse large b-cell lymphoma, hodgkin disease, leukemia, lymphoma